Literature DB >> 15297960

Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images.

Jeffrey D Seidman1, Robert A Soslow, Russell Vang, Jules J Berman, Mark H Stoler, Mark E Sherman, Esther Oliva, Andre Kajdacsy-Balla, David M Berman, Larry J Copeland.   

Abstract

The National Cancer Institute sponsored a Borderline Ovarian Tumor Workshop held in August 2003 in Bethesda, MD. This report was developed from discussions at the Workshop. The participants acknowledged several areas of disagreement on basic terminology issues and agreed that a glossary with example images would help clarify many commonly misunderstood issues. This report defines terminology used in the pathological description of borderline tumors and their variants, and illustrates examples of each of the most common entities. It also addresses controversial aspects of the definitions and issues involving specimen handling and reporting. For those issues where there is disagreement, the terminology and diagnostic approaches reflecting the differing views are presented.

Entities:  

Mesh:

Year:  2004        PMID: 15297960     DOI: 10.1016/j.humpath.2004.03.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  26 in total

1.  Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Authors:  Sarah J Nyante; Amanda Black; Aimée R Kreimer; Máire A Duggan; J Daniel Carreon; Bruce Kessel; Saundra S Buys; Lawrence R Ragard; Karen A Johnson; Barbara K Dunn; Lois Lamerato; John M Commins; Christine D Berg; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2010-12-07       Impact factor: 5.482

2.  Whole exome sequence analysis of serous borderline tumors of the ovary.

Authors:  Jeff Boyd; Biao Luo; Suraj Peri; Beth Wirchansky; Lucinda Hughes; Caitlin Forsythe; Hong Wu
Journal:  Gynecol Oncol       Date:  2013-06-14       Impact factor: 5.482

Review 3.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

Review 4.  [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

5.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

6.  Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Authors:  Kruti P Maniar; Yihong Wang; Kala Visvanathan; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

Review 7.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

8.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

9.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Kirsten Frederiksen; Anette Kjaerbye-Thygesen; Klaus Kaae Andersen; Ann Tabor; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

Review 10.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.